Current treatment for chronic hepatitis C virus/HIV-infected individuals

Bhagani, Sanjay

doi:10.1097/coh.0b013e32834bd257

Cited by 20 publications

(11 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason might be the combination of the high-dose recombinant adenovirus and ribavirin. The combination of ribavirin and human IFN-a protein is a common treatment method for human hepatitis C (Bhagani, 2011). Therefore, we suggest that ribavirin might interfere with the expression of porcine IFN-a in the recombinant adenovirus, or a part of ribavirin might inhibit the adenovirus.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents

et al. 2012

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) is an economically significant animal disease because of the speed of its transmission. The current FMD vaccine provides no protection until 7days after the vaccination, which reduces its effectiveness in the case of an outbreak. Therefore, to find an alternative method of applying antiviral agents for rapid and enhanced inhibition of the FMD virus (FMDV), we compared the antiviral effects of promising antiviral agents and attempted to apply them in combination. First, we measured and compared the 50% effective concentration (EC(50)) to the mean inhibition effects of FMDV, and the 50% cytotoxic concentration (CC(50)) to the mean cytotoxicity of antiviral agents such as ribavirin, guanidine-hydrochloride (guanidine-HCl), 6-azauridine, and recombinant adenovirus expressing three small interference RNAs (Ad-siRNA) or porcine interferon-α (Ad-porcine IFN-α) in swine kidney cells (IBRS-2). The selectivity indices of ribavirin (35.2) and 6-azauridine (34.6) were higher than that of guanidine-HCl (26.9). The selectivity indices of Ad-siRNA or Ad-porcine IFN-α were 7×10(3) or 7×10(4) based on the adenoviral titer. Next, we tested the combined effects of the FMDV inhibition agents. Enhanced inhibition effects were observed in the IBRS-2 cells and in suckling mice from the combination of Ad-porcine IFN-α and Ad-siRNA or ribavirin. The combined application of these recombinant adenoviruses and ribavirin may enhance their inhibitory effect on FMDV and overcome FMDV resistance against antiviral agents.

show abstract

Section: Discussionmentioning

confidence: 95%

“…Therefore, we anticipated that combination treatment using antiviral agents with different inhibition mechanisms would be more effective at circumventing FMDV resistance. Combination antiviral therapy has become standard for some human disease viruses, for example, the human immunodeficiency virus and human hepatitis C virus (Bhagani, 2011).…”

Section: Discussionmentioning

confidence: 99%

Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Thus, the known antiviral effects of IFN-α and knowledge of its dysfunction in HIV infection has led to studies investigating its use as a potential therapeutic. IFN-α has been used as therapy for HIV mono-infection, but most of the more recent studies utilizing IFN-α as a therapeutic involve patients who are HIV/HCV co-infected (reviewed in [84]). However, the first in vivo studies of IFN-α as a therapeutic were undertaken in the very early days of the pandemic, with treated Kaposi’s sarcoma (KS) patients showing tumor regression and reduced HIV p24 levels.…”

Section: Potential Therapeutic Roles Of Cytokines In Hivmentioning

confidence: 99%

Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development

Keating

Jacobs

Norris

2012

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

“…This treatment produces rates of sustained virologic response (SVR) of around 40‐50% in patients infected with HCV genotype (HCV‐GT) 1, 60% in HCV‐GT 4, and 80% in HCV‐GT 2/3. Additionally, recent analyses have revealed that the use of pegIFNα/ribavirin in HIV/HCV‐coinfected patients may provide SVR rates which approximate those of HCV‐monoinfected patients . Current CHC therapy involves new direct‐acting antivirals plus pegIFNα/ribavirin, which has further improved the SVR rate .…”

mentioning

confidence: 99%

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis

et al. 2014

View full text Add to dashboard Cite

There is growing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity. We analyzed the relationship of vitamin D status with advanced liver fibrosis (ALF) in CHC treatment‐naïve patients and sustained virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNα/ribavirin) therapy. We performed a meta‐analysis of all eligible studies published to date (April, 2014) in PubMed, SCOPUS, LILACS, and the Cochrane Library, assessing plasma/serum vitamin D levels related to ALF and/or SVR. Pooled odds ratios (ORs) were estimated by either fixed or random effects models. Fourteen studies were selected from the literature search, seven for ALF (1,083 patients) and 11 for SVR (2,672 patients). For liver fibrosis, low vitamin D status was related to a diagnosis of ALF, with the cutoffs of 10 ng/mL (OR = 2.37, 95% confidence interval [CI] = 1.20, 4.72) and 30 ng/mL (OR = 2.22, 95% CI = 1.24, 3.97) being significant, and a near‐significance for 20 ng/mL (OR = 1.44, 95% CI = 0.99, 2.12). Regarding SVR, a significant heterogeneity among studies was found (P < 0.001), and we only found a significant association with SVR for a vitamin D cutoff of 20 ng/mL (OR = 0.53, 95% CI = 0.31, 0.91). When meta‐analysis was performed excluding the outliers, significant pooled ORs were found for all patients (10 ng/mL [OR = 0.48, 95% CI = 0.34, 0.67] and 20 ng/mL [OR = 0.58, 95% CI = 0.45, 0.76]) and GT1/4 patients (10 ng/mL [OR = 0.53, 95% CI = 0.34, 0.81] and 20 ng/mL [OR = 0.54, 95% CI = 0.39, 0.74]). Conclusion: Low vitamin D status in CHC patients is associated with a higher likelihood of having ALF and lower odds of achieving SVR following pegIFNα/ribavirin therapy. (Hepatology 2014;60:1541–1550)

show abstract

Current treatment for chronic hepatitis C virus/HIV-infected individuals

Abstract: Peg-IFN/RBV therapy plays an important role in the management of HCV in HIV-infected patients. Efforts to maximize response to current therapy need to continue while we await new therapies.

Cited by 20 publications

References 85 publications

Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents

Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents

Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis

Contact Info

Product

Resources

About